BFM
IMMX icon

Boothbay Fund Management’s Immix Biopharma IMMX Stock Holding History

Boothbay Fund Management’s Portfolio IMMX Stock Details IMMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-33,600
Closed -$76.9K – 2313
2022
Q4 		$76.9K Buy
+33,600
New +$44.8K ﹤0.01% 1845

Other funds holding IMMX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UB
UMB Bank Kansas City, Missouri $7.16B AUM 20.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MAWA
Moss Adams Wealth Advisors Seattle, Washington $1.6B AUM 28.24% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
ICG
InterOcean Capital Group Nashville, Tennessee $4.19B AUM 26.29% 1-Year Est. Return
GSC
Ground Swell Capital Folly Beach, South Carolina $50.7M AUM 30.19% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Boothbay Fund Management's IMMX Position: Q1 2023 in Review

Boothbay Fund Management sold out of Immix Biopharma (IMMX) in Q1 2023, closing a stake of 33,600 shares — an estimated $76.9K sold.

Boothbay Fund Management first reported a position in IMMX in Q4 2022 and held it in 1 quarter. The position peaked at $76.9K in Q4 2022. 12 funds tracked by Wall St. Rank hold IMMX as of Q1 2023.

  • Boothbay Fund Management reported no remaining Immix Biopharma position as of Q1 2023 after selling out during the quarter.
  • Boothbay Fund Management sold 33,600 Immix Biopharma shares in Q1 2023, an estimated $76.9K.
  • Boothbay Fund Management first reported a position in Immix Biopharma in Q4 2022 and held it in 1 quarter.
  • Boothbay Fund Management's Immix Biopharma position peaked at $76.9K in Q4 2022.
  • 12 funds tracked by Wall St. Rank held Immix Biopharma as of Q1 2023.

Based on Boothbay Fund Management's 13F filing for Q1 2023, filed 15 May 2023.